DG DISPATCH: APA: Treating Premenstrual Dysphoric Disorder
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH: APA: Treating Premenstrual Dysphoric Disorder

By Lara Pullen
Special to DG News

CHICAGO, IL -- May 23, 2000 -- Results from several clinical trials indicate that the selective serotonin reuptake inhibitors (SSRIs) have excellent efficacy and minimal side effects in the treatment of premenstrual dysphoric disorder (PMDD). Dr. Meir Steiner of McMaster University, Ontario, Canada reviewed several randomized, placebo-controlled trials studying the effects of SSRIs on the treatment of PMDD at the 2000 Annual Meeting of the American Psychiatric Association,

Several SSRI's (fluoxetine, sertraline, paroxetine, clomipramine, fluvoxamine, and citalopram) have been tested for efficacy in the treatment of PMDD and it is difficult to distinguish between them in terms of efficacy. Clomipramine at 25-75 mg was found to be significantly more effective than placebo in reducing irritability as well as other symptoms associated with PMDD (n = 20). In a randomized, controlled trial (n = 65), paroxetine treatment resulted significant reduction in irritability, depression, anxiety, appetite, bloating, and breast tenderness. Another randomized, controlled trial demonstrated that sertraline treatment resulted in significantly decreased depressive symptoms, physical symptoms, and anger/irritability. In the case of clomipramine, paroxetine, and, perhaps, other SSRI's, three cycles of treatment seemed to be required for maximum efficacy.

Dr. Steiner concluded by stating that, "Women who are being diagnosed with PMDD are not seeking treatment or help… so the onus is on us to identify them."

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities